Takeda Pharmaceutical ADR saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, rising from 65 to 73.
Can You Really Time The Stock Market?
IBD's proprietary RS Rating identifies market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the last 52 weeks matched up against all other stocks.
History shows that the market's biggest winners often have an 80 or better RS Rating in the early stages of their moves. See if Takeda Pharmaceutical ADR can continue to show renewed price strength and hit that benchmark.
Takeda Pharmaceutical ADR is in a buying range after moving past a 15.42 entry in a cup with handle. Once a stock moves 5% or higher beyond the initial entry, it's considered out of buy range.
While earnings growth decreased in the company's most recent quarterly report from -21% to -33%, sales grew 1%, up from -8% in the previous report. The company is expected to report its latest numbers on or around Jul. 30.
The company earns the No. 9 rank among its peers in the Medical-Ethical Drugs industry group. Phibro Animal Health, Novartis ADR and Indivior are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Technical Action?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
